Drugs / Neoantigen mRNA Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06195384 | May 2024 → Dec 2027 expected | cancer | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen mRNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06195384 ↗ |
| Modality | Messenger RNA (mRNA) | “appropriate mRNA sequences will be verified, manufactured and protected for vaccine production” NCT06195384 ↗ |
| Route | Other | “deliver the vaccine into selected patients via local injections” NCT06195384 ↗ |